Brief: VBL Therapeutics Announces Peer-Reviewed Publication Of Positive Results Of Pre-Specified Interim Analysis Of Oval, A Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer
04/03/2021 12:11
March 4 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS ANNOUNCES PEER-REVIEWED PUBLICATION OF
POSITIVE
RESULTS OF PRE-SPECIFIED INTERIM ANALYSIS OF OVAL, A PHASE 3
REGISTRATION ENABLING STUDY OF VB-111 IN OVARIAN CANCER
Source text for Eikon: ID:nGNX2vHTsm
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives